. FLT is a marker for cellular proliferation 4 , which is associated with treatment failure 5 . Both tracers have previously been proposed as possible dose painting targets 6, 7 . In this work we investigated the spatiotemporal stability of Cu-ATSM and FLT PET in canine patients after receiving 8.4-15 Gy of traditional radiotherapy. Experimental Setup: Our experimental setup has several features that make it well-suited for measuring tracer stability during therapy. Spontaneously-occurring canine tumors are large and resemble the biologic complexity of human cancers 8 . Patients were immobilized by patientspecific dental-impression molds that attach rigidly to the scanner couch (see Figure 1 ). Rotations were further restricted by a patient-specific vacuum mattress. All mid-treatment scans were rigidly registered to pre-treatment scans via CT registration. These immobilization techniques enabled highly reproducible positioning of the patient, with average registration offsets on the order of 1 mm. With such reproducible positioning, we were able to compare SUVs at pre-and mid-treatment voxel-byvoxel, with a high degree of confidence that registration errors are negligible. Spearman correlation coefficients were calculated to quantify the agreement between pre-and mid-treatment PET distributions. In addition, we compared the magnitude of tracer uptake in the GTV at pre-and mid-therapy using the mean SUV, maximum SUV, total summed SUV, and peak SUV. Peak SUV is the mean SUV in a 1 cm diameter sphere centered at SUV max . Paired t-tests determined significant differences. Results: Voxel-by-voxel correlations of pre-and mid-treatment SUVs are shown in Figure 1 . Canine patients are immobilized using a patient-specific dental mold and bite block that are fixated to the scanner couch. Table 1 . Pre-and mid-treatment Cu-ATSM scans had slightly higher (non-significant) correlations than FLT scans. Sarcoma tumors also had slightly higher (non-significant) correlations than carcinoma tumors. Table 2 shows the SUV measures that were significantly smaller at mid-treatment than at pre-treatment. Only Cu-ATSM in sarcoma patients showed no significant reduction (p > 0.20) in tracer uptake. Conclusions: Both FLT and Cu-ATSM are generally stable during early radiotherapy. This implies that, even though the magnitudes of hypoxia and proliferation often decrease after a few fractions, the most hypoxic tumor regions at pre-treatment usually remain the most hypoxic during radiotherapy. The same is true for the tumor's most proliferative regions. If Cu-ATSM or FLT are used as dose painting targets, the hypoxic and proliferative targets should remain stable during therapy, and will likely not require adaptive therapy. Further biologic validation, however, is required before FLT and Cu-ATSM can be considered viable dose painting targets. Four examples of individual patient scatter plots are also shown, two for FLT scans and two for Cu-ATSM scans. Table 2 . SUV measures that were significantly less (p<0.05) at mid-treatment than at pre-treatment, as determined by paired t-tests.
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